Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-TROPISM: Empagliflozin in Non-Diabetic HFrEF
NCT03485222Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Icahn School of Medicine at Mount Sinai. Started May 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03485222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485222.